Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Fanconi Anemia × prexasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Prostatic Neoplasms 1 Ovarian Neoplasms 1 Hereditary Breast and Ovarian Cancer Syndrome 1 Fanconi Anemia 1 Central Nervous System Neoplasms 1 Breast Neoplasms 1

Interventions

fludarabine phosphate 2 Antilymphocyte Serum 2 thymoglobulin 1 prexasertib 1 fludarabine 1 Whole-Body Irradiation 1 Melphalan 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Cyclophosphamide 1 Busulfan 1 AP 1903 reagent 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02873975 2022-10-21

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Dana-Farber Cancer Institute

Phase 2 Completed

27 enrolled 13 charts

Classical hematology

Fanconi Anemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡